Telephone
61.3.9548.7586
Address
23 Normanby Road Notting Hill, Victoria (VIC) 3168
Description
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. Its activities include research and development of non-invasive diagnostic tests for early detection of cancer, based on certain proprietary intellectual property. The company was founded on June 30, 1983 and is headquartered in Subiaco, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.46 - 0.99
Trade Value (12mth)
AU$12,521.00
1 week
0.85%
1 month
0.85%
YTD
-7.81%
1 year
-6.35%
All time high
61.1211
EPS 3 yr Growth
36.000%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-28.70%
ROIC
-36.70%
Interest Coverage
-151.60
Quick Ratio
6.20
Shares on Issue (Fully Dilluted)
92m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 January 23 |
Appendix 4C & Quarterly Activities Report - December 2022
×
Appendix 4C & Quarterly Activities Report - December 2022 |
31 January 22 |
Appendix 4C & Quarterly Activities Report
×
Appendix 4C & Quarterly Activities Report |
31 January 22 |
Notification regarding unquoted securities - IIQ
×
Notification regarding unquoted securities - IIQ |
30 October 23 |
Appendix 4C and Quarterly Activities Report - September 2023
×
Appendix 4C and Quarterly Activities Report - September 2023 |
30 November 23 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
30 November 22 |
Change in substantial holding
×
Change in substantial holding |
30 June 23 |
Notification of cessation of securities - IIQ
×
Notification of cessation of securities - IIQ |
30 August 23 |
Appendix 4E and Preliminary Financial Report
×
Appendix 4E and Preliminary Financial Report |
30 August 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 August 22 |
Appendix 4E and Preliminary Financial Report
×
Appendix 4E and Preliminary Financial Report |
29 November 23 |
2023 AGM CEO Presentation
×
2023 AGM CEO Presentation |
29 November 23 |
2023 AGM Results of Meeting
×
2023 AGM Results of Meeting |
29 June 23 |
SubB2M/CA15.3 Clinical Validation Data Investor Presentation
×
SubB2M/CA15.3 Clinical Validation Data Investor Presentation |
29 December 21 |
INOVIQ Appendix 4G and Corporate Governance Statement
×
INOVIQ Appendix 4G and Corporate Governance Statement |
29 April 22 |
IIQ Appendix 4C & Quarterly Activities Report - March 2022
×
IIQ Appendix 4C & Quarterly Activities Report - March 2022 |
28 September 22 |
2022 Annual Report and update on results
×
2022 Annual Report and update on results |
28 October 22 |
IIQ Appendix 4C & Quarterly Activities Report-September 2022
×
IIQ Appendix 4C & Quarterly Activities Report-September 2022 |
28 November 22 |
INOVIQ Settles Legal Proceedings
×
INOVIQ Settles Legal Proceedings |
28 November 22 |
CEO AGM Presentation
×
CEO AGM Presentation |
28 November 22 |
Results of 2022 Annual General Meeting
×
Results of 2022 Annual General Meeting |
28 March 22 |
Update on Legal Proceedings and BARD1 Autoantibody Program
×
Update on Legal Proceedings and BARD1 Autoantibody Program |
28 July 23 |
Appendix 4C and Quarterly Activities Report - June 2023
×
Appendix 4C and Quarterly Activities Report - June 2023 |
28 April 23 |
Appendix 4C and Quarterly Activities Report - March 2023
×
Appendix 4C and Quarterly Activities Report - March 2023 |
27 September 23 |
Notice required under Listing Rule 3.13.1
×
Notice required under Listing Rule 3.13.1 |
27 September 23 |
2023 Annual Report
×
2023 Annual Report |
27 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
27 October 22 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.